Acquisition, Discontinuation of Operations and Deconsolidation of Vitel and Oncbiomune Mexico (Details Narrative) - USD ($)			12 Months Ended
	Mar. 10, 2017	Mar. 07, 2017	Dec. 31, 2018	Dec. 31, 2017
Acquisition percentage of issued and outstanding				50.00%
Business acquisition description	The Common Stock and Series B Preferred will be held by Trustee for the benefit of the Vitel Stockholders as provided for in the Trust Agreement and 98% of the Vitel Shares are held by Banco Actinver for the benefit of the Company as provided for in the Trust Agreement and 2% of the Vitel Shares were transferred to the Company. Vitel became a wholly owned subsidiary of the Company as of the Closing Date as the Company has full control of the Vitel Shares through the Trust.
Share price, per share	$ 0.25			$ 0.075
Number of unregistered shares of common stock issued				61,158,013
Number of unregistered shares of common stock value				$ 4,587,351
Increase in goodwill and other intangible assets				23,221
Goodwill and other intangible assets			$ 4,718,817
Fair value of net asset acquired			4,695,596
Acquisition loss on impairment				4,760,646
Impairment of intangible assets				4,718,817
Legal fees				104,000
Liabilities of discontinued operation			$ 686,547	694,996
Drug Formula [Member]
Impairment of intangible assets				$ 41,096
Vitel Stockholders [Member]
Acquisition percentage of issued and outstanding	100.00%
Series B Preferred Stock [Member]
Stockholder voting rights		Each share of Series B preferred stock entitles the holder to 100 votes on all matters submitted to a vote of the Company's stockholders.
Number of unregistered shares of common stock issued				5,000,000
Number of unregistered shares of common stock value				$ 500
Preferred stock, shares outstanding			7,892,000	7,892,000
Preferred stock nominal value			$ 789	$ 789
Series B Preferred Stock [Member] | Jonathan F. Head [Member]
Number of shares issued	2,892,000
Number of shares issued, value	$ 289
Share price, per share	$ 0.0001
Common Stock [Member]
Number of shares issued, value			$ 52,500
Share price, per share			$ 0.021
Number of unregistered shares of common stock issued				61,158,013
Number of unregistered shares of common stock value				$ 6,116
Contribution Agreement [Member] | Series B Preferred Stock [Member]
Number of shares issued	5,000,000
Contribution Agreement [Member] | Common Stock [Member]
Number of shares issued	61,158,013
Stockholders Agreement [Member]
Debt interest rate description			Right of Co-Sale (Tag Along). In the event that any stockholder who is a party to the Stockholders' Agreement or group of such stockholders intends to accept an offer (either solicited or unsolicited) from any third party to acquire or otherwise transfer Company Securities (as defined in the Stockholders' Agreement), representing at least 20% of the outstanding Company Securities, on a fully diluted basis, the selling stockholder shall give an offer notice in writing to the other stockholders of the Company who are a party to the Stockholders' Agreement, with a copy to the Company, containing the terms and conditions of such offer received from the interested third party. Each such stockholder shall have the right to participate in such offer by selling the pro rata proportion of its Company Securities pursuant to such offer to acquire or otherwise Transfer Company Securities (as defined in the Stockholders' Agreement).
Common stock outstanding, percentage description			Drag Along. In the event a stockholder who is a party to the Stockholders' Agreement or group of such stockholders representing at least 32% (thirty two per cent) of the outstanding Company Securities, on a fully diluted basis, intends to accept an offer from any third party to acquire or otherwise Transfer Company Securities, representing at least 50% of the outstanding Company Securities, on a fully diluted basis, and the transaction is approved by the Board of Directors as a Major Decision, then each such stockholder shall be obligated to sell its Company Securities pursuant to the offer to purchase. In case the drag along provision included herein is enforced, all the stockholders participating in such sale shall receive the same terms and conditions of sale based on their respective holdings of Company Securities and shall otherwise be treated equally based on such ownership interest.
Stockholders Agreement [Member] | Maximum [Member]
Diluted shares percentage			5.00%
Stockholders Agreement [Member] | Series B Preferred Stock [Member]
Number of shares issued			5,000,000
Stockholder voting rights			Series B Preferred Stock with 100 votes per share
Stockholders Agreement [Member] | Common Stock [Member]
Number of shares issued			61,158,013
Irrevocable Management Trust Agreement [Member]
Business acquisition transfer of shares	98
Subscription Agreements [Member] | Series B Preferred Stock [Member] | February 20, 2019 [Member]
Share price, per share			$ 0.0001
Preferred stock, shares outstanding			5,000,000
Preferred stock nominal value			$ 500
Vitel Laboratorios, S.A. de C.V [Member]
Acquisition percentage of issued and outstanding	100.00%